Literature review and protocol for a prospective multicentre cohort study on multimodal prediction of seizure recurrence after unprovoked first seizure

• Published in: BMJ open 2024-04, Vol.14 (4), p.e086153
• Main Authors: Beattie, Brooke C, Batista García-Ramó, Karla, Biggs, Krista, Boissé Lomax, Lysa, Brien, Donald C, Gallivan, Jason P, Ikeda, Kristin, Schmidt, Matthias, Shukla, Garima, Whatley, Benjamin, Woodroffe, Stephanie, Omisade, Antonina, Winston, Gavin P
• Format: Article
• Language: English
• Subjects: Adult; Anxiety; Biomarkers; Brain research; Cognition; Cohort analysis; Comorbidity; Convulsions & seizures; Electroencephalography; Epilepsy; Epilepsy - epidemiology; Humans; Machine Learning; Magnetic Resonance Imaging; Mental depression; Multicenter Studies as Topic; Neurology; Nova Scotia; Prospective Studies; Recurrence; Seizures - epidemiology
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2024-086153

IntroductionEpilepsy is a common neurological disorder characterised by recurrent seizures. Almost half of patients who have an unprovoked first seizure (UFS) have additional seizures and develop epilepsy. No current predictive models exist to determine who has a higher risk of recurrence to guide treatment. Emerging evidence suggests alterations in cognition, mood and brain connectivity exist in the population with UFS. Baseline evaluations of these factors following a UFS will enable the development of the first multimodal biomarker-based predictive model of seizure recurrence in adults with UFS.Methods and analysis200 patients and 75 matched healthy controls (aged 18–65) from the Kingston and Halifax First Seizure Clinics will undergo neuropsychological assessments, structural and functional MRI, and electroencephalography. Seizure recurrence will be assessed prospectively. Regular follow-ups will occur at 3, 6, 9 and 12 months to monitor recurrence. Comparisons will be made between patients with UFS and healthy control groups, as well as between patients with and without seizure recurrence at follow-up. A multimodal machine-learning model will be trained to predict seizure recurrence at 12 months.Ethics and disseminationThis study was approved by the Health Sciences and Affiliated Teaching Hospitals Research Ethics Board at Queen’s University (DMED-2681-22) and the Nova Scotia Research Ethics Board (1028519). It is supported by the Canadian Institutes of Health Research (PJT-183906). Findings will be presented at national and international conferences, published in peer-reviewed journals and presented to the public via patient support organisation newsletters and talks.Trial registration numberNCT05724719.